NTX-301 is under clinical development by Pinotbio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NTX-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NTX-301 is under development for the treatment of chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia, relapsed and refractory acute myeloid leukemia, myelodysplastic syndrome. It is administered through oral route. It acts by targeting DNA methyltransferase1 (DNMT1).
It was also under development for the treatment of high-grade glioma, glioblastoma multiforme (GBM), solid tumor, ovarian cancer, transitional cell carcinoma (urothelial cell carcinoma), bladder cancer
Pinotbio, a biotechnology company that engaged in the development of new small-molecule. The company is headquartered in Republic of Korea (South Korea).
For a complete picture of NTX-301’s drug-specific PTSR and LoA scores, buy the report here.